About Onkologic
Onkologic is a company based in Farmington (United States) founded in 2021 by Rachit Ohri. Onkologic has raised $305 thousand across 1 funding round. Onkologic offers products and services including Enable-NK™ Duo, Enable-NK™ Grow, and Enable-NK™ Activate. Onkologic operates in a competitive market with competitors including Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio, among others.
- Headquarter Farmington, United States
- Founders Rachit Ohri
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Onkologic, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$305 K (USD)
in 1 rounds
-
Latest Funding Round
$305 K (USD), Seed
Apr 29, 2022
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Onkologic
Onkologic offers a comprehensive portfolio of products and services, including Enable-NK™ Duo, Enable-NK™ Grow, and Enable-NK™ Activate.
Formulation for growing and activating Natural Killer cells in therapies.
Media component to optimize NK cell growth and reduce exhaustion.
Media for enhancing NK cell performance in immunotherapies.
Funding Insights of Onkologic
Onkologic has successfully raised a total of $305K through 1 strategic funding round. The most recent funding activity was a Seed round of $305 thousand completed in April 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Onkologic
Investment portfolio details for Onkologic
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Onkologic
Detailed financials for Onkologic
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Onkologic Comparisons
Peer comparison for Onkologic
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Onkologic
Onkologic operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Multus, Metatissue, Nu-Tek Biosciences, Kohjin Bio and Sarvoshadhi Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of lab-grown meat alternatives
|
|
| Locked | Locked | Locked |
Provider of human protein-based products for cell culture, tissue engineering, and disease modeling applications
|
|
| Locked | Locked | Locked |
Develops innovative animal-free peptones and cell culture media for pharmaceutical use.
|
|
| Locked | Locked | Locked |
Tissue culture media provided for regenerative medicine and immunotherapy research.
|
|
| Locked | Locked | Locked |
Customized cell culture media for biotechnology are developed.
|
|
| Locked | Locked | Locked |
Developer of cell culture medium for pharmaceutical screening and personalized medicine
|
Detailed competitors of Onkologic
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Onkologic
Complete news archive for Onkologic
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Onkologic
Onkologic was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Onkologic is headquartered in Farmington, United States.
Rachit Ohri is the current CEO of Onkologic. They have also founded this company.
Onkologic is a funded company, having raised a total of $305K across 1 funding round to date.
Onkologic was founded in 2021 and is based in Farmington, United States. Operations focus on the biotechnology sector, where reformulated NK cell media products are provided to enhance the efficacy and potency of NK cellular immunotherapies against cancer. Formulations for CD56 immune cells, including gamma-delta T cells, are also offered to support related cell therapy applications.
Onkologic's top competitors include Multus, Cellular Engineering Technologies and Metatissue.
Onkologic offers Enable-NK™ Duo, Enable-NK™ Grow, and Enable-NK™ Activate.